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ABSTRACT Although planarians are established model organisms in developmental biology and
regeneration studies, in the last forty years or so, they have caught the attention of pharmacologists, especially to study the pharmacology of drugs of abuse. This review covers the following
topics: some fundamentals of the history of animal models and planarians in biomedical research;
an abbreviated story of systematic pharmacology research using planarians as a model organism;
an example of how planarians are contributing to the search for compounds against acute cocaine
toxicity; an analysis of the number of papers on planarians and pharmacological topics from 19002016; some perspectives on pharmacology in developmental and regeneration studies, arguing
in favor of the planarian model as a leading subject for this interdisciplinary area of research, and
finally some concluding thoughts.
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Introduction
The study of model organisms for the purpose of uncovering
fundamental biological principles is a leading source of multiple
applications relevant to the medical sciences. When the original
natural philosophers studied nature for pure knowledge’s sake,
they mainly followed Aristotle’s maxim: “Philosophy starts in wonder and wonderment” (Aristotle, 384 BC). In time, not long after
the medical sciences diverged from pure natural history, their true
development was based on experimental science and the use of
model organisms to better further our grasp of normal physiological
mechanisms in humans, a tradition that continues to this day. As a
consequence of this tradition, studies based on model organisms
allow us to learn about the diseases that arise upon disruption of
normal human physiology.
Most scholars agree that the beginnings of animal experimentation for the explicit purpose of advancing the biomedical sciences
began in the 1800s with the French scientist Claude Bernard, the
father of experimental physiology (Barker Jørgensen, 2001). Later
on, in the early 20th century the Danish experimental physiologist
and Nobelist August Krogh independently articulated Bernard’s
insights when he stated:
“For a large number of [biological] problems there will be some
animal of choice, or a few such animals, on which it can be most
conveniently studied” (Krogh, 1929).

This statement lies at the heart of modern biomedical research,
and was eventually formalized as “The Krogh Principle”. This
formalization was an idea of another Nobelist, Hans Krebs of the
Tricarboxylic Acid Cycle fame—among several other important
biochemical discoveries—(Krebs, 1975). Biologists have applied
Krogh’s Principle to virtually every aspect of the life sciences, but
most importantly for the purposes of this review, to developmental
and regeneration biology (Barker Jørgensen, 2001; Lindstedt,
2014). The contributions of virtually every model organism to experimental biology are exemplary illustrations of Krogh’s Principle
in action. Nevertheless, it is important not to lose sight of the fact
that no particular organism is useful for every research problem.
Also, not all aspects of the normal physiology of model organisms
represent an ideal surrogate for human biology. These apparent
deviations from Krogh’s Principle were articulated by refining the
principle through the following corollary:
“No single organism (or technique) exists that can provide easy
access to the diversity of hidden mechanisms that underlie all interesting and important physiological and biochemical problems”
(Wayne and Staves, 1996).
Although Krogh expressed his views on animal models in light
of his own area of expertise (comparative physiology) and emphatically argued in favor of the practical applications of research, he,
as Aristotle before him, possessed a keen aesthetic appreciation
for the joy of pure biological knowledge. In Krogh’s words:
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“You will find in the lower animals mechanisms and adaptations
of exquisite beauty and the most surprising character…” (Krogh,
1929).
I could not agree more with Krogh’s appreciation of “lower
animals”, as I happen to work with one, a type of living being that
exemplifies Krogh’s practical yet lyrical description with distinction.
This organism is the planarian.

Planarians
Although “planaria” and its derivations (planarian, planarians)
are widely used to describe a specific type of common invertebrate,
there is a minor controversy among specialists about using these
terms in a formal scientific setting. Through informal conversations
with colleagues, as well as by examining the scientific literature, it
is evident that “planaria” is a rather nonspecific way of naming the
organisms of interest. In essence, planarian merely means “flatworm”, which by itself usually refers to a wide variety of organisms
which may or may not be closely related phylogenetically (Egger
et al., 2009). In fact, experts in the field have argued in favor of
permanently discontinuing the use of “planaria” in the scientific
literature (Egger et al., 2007). Only time will tell if this idea gains
traction. Nonetheless, in this review, I will use “planaria” and related
terms as traditionally used. In order to help in this discussion, I will
define and describe what they are in the next paragraphs.
Planarians are essentially a series of several species of free-living
flatworms that display bilateral symmetry. For the purposes of this
review the planarians most commonly used for scientific research
belong to the phylum Platyhelminthes, whose most famous and
highly successful members include a variety of obligate parasites
that are beyond of the scope of this review (Collins, 2017). The
best known examples of the free-living Platyhelminthes belong to
the order Tricladida, a classification criterion based on specific aspects of their digestive system morphology (Rohde, 2000). Triclads
are traditionally further classified based on an ecological context,
namely whether they live in freshwater, marine, or terrestrial environments. This ecological classification scheme of triclads is not
universally accepted and is under revision using molecular biology
approaches (Alvarez-Presas et al., 2008; Riutort et al., 2012). Most
of the planarian species used as research animals are freshwater
species. The most common genera used in research are Girardia,
Dugesia; (Fig. 1), Schmidtea, Phagocata, and Polycelis (Elliott

Fig. 1. Planarian specimen (Girardia sp.) over a 1-cm gridline. Picture
credit: Pagán Laboratory.

Fig. 2. Cover of Müller’s Prodromus (left) and the page where “planaria”
appeared for the first time (right). Please note that at the time, planarians were classified as mollusks. Photograph courtesy of Dr. Masaharu
Kawakatsu, used with permission.

and Sánchez Alvarado, 2013, Newmark and Sánchez Alvarado,
2002; Saló and Baguñà, 2002; Tessmar-Raible and Arendt, 2003).
Girardia and Dugesia are the best-known genera with about 75
identified species so far (Riutort et al., 2012).
Historically, it seems that the earliest printed reference of the
term “planaria” came from the Danish naturalist Othone Friderico
Müller in a 1776 book titled “Zoologiae Danicae Prodromus” (Fig.
2). It is to be noted that many of the flatworm species that Müller
called “planarians” are currently placed into other taxa of the class
turbellaria or the phylum rhynchocoela (Alvarez-Presas et al., 2008;
Riutort et al., 2012).
Although it is undisputable that Müller deserves priority recognition for the use of the term “planaria”, two years before Müller’s
book, in 1774, the German naturalist Peter Simon Pallas published
his book Spicilegia Zoologica, where he showed drawings of several worms which for all intent and purposes look like planarians.
However, he listed these worms as Fasciola, a name that now is
reserved for a genus of parasitic flatworms (Fig. 3). His drawings
were so precise and detailed that modern specialists are able to
identify the depicted planarian species with a high level of certainty.
In the best tradition of the scientific “Age of Wonder” of the 1700s1800s, planarians were enthusiastically studied by the naturalists of
the time, including Charles Darwin (Elliott and Sánchez Alvarado,
2013; Rieger, 1998; http://darwin-online.org.uk/). Even the father
of modern genetics, Thomas Hunt Morgan, studied planarians.
Between 1898 and 1905, Morgan published a series of papers
and books on the general topic of regeneration, with planarians as
one of the main research subjects (Sturtevant, 1959). According
to Morgan himself, planarians came to his attention by reading a
paper by Dr. Harriet Randolph, of Bryn Mawr College (Randolph,
1897). Randolph and Morgan collaborated in subsequent works.
In great part as a consequence of this collaboration, Morgan even
seriously considered planarians as his choice of model organism
to study the cellular basis of genetics before favoring the fruit fly,
Drosophila melanogaster (Adell et al., 2010; Gentile et al., 2011;
Newmark and Sánchez Alvarado, 1999; Pagán, 2014, chapter 7).
There is little doubt that if planarians had been Morgan’s choice,
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Fig. 3. Cover of Pallas’ Spicilea Zoologica (left) and the page showing
some worms which are very much like planarians (right). Photograph
courtesy of Dr. Masaharu Kawakatsu, used with permission.

the history of 20th century genetics could have featured a different
protagonist!
The history of planarians in biology is quite curious to say the
least. There were two specific time periods in which despite an
initial interest in the worms, researchers stopped using them as
animal models in favor of other organisms, for a variety of reasons. Some authors have speculated on the specific reasons for
this apparent decline of scientific interest. The first of such time
periods was around Morgan’s time, in a series of well-documented
episodes described and analyzed in detail in a work appropriately
titled: “Whatever happened to planaria?” (Mitman and FaustoSterling, 1992).
The reason for the second time period of low popularity of
planarians (roughly the 1950s-1960s) is not entirely clear and is
therefore more debated, but this seemed to be related to the (at
the time controversial) research by James McConnell on memory
transfer experiments using planarians (Rilling, 1996). McConnell
also worked, albeit somewhat less controversially, on memory
retention in trained planarians upon decapitation and brain regeneration (reviewed in Corning and Ratner, 1967; Pagán, 2014;
Rilling, 1966). Incidentally, McConnell’s memory retention work
has recently been replicated using computerized procedures and
properly designed controls, which renders the concept valid beyond
any scientific doubt (Blackiston et al., 2015; Neuhof et al., 2016;
Shomrat and Levin, 2013). Memory research using planarians is
undoubtedly experiencing an exciting resurgence, but this topic
is beyond the scope of this review.
Planarians are uniquely situated to contribute to several scientific
disciplines, including neurobiology. In evolutionary terms, they are
some of the simplest examples of organisms displaying bilateral
symmetry and cephalization, including a primitive “brain”, with
many features similar to vertebrate nervous systems (Sarnat and
Netsky, 1985, 2002). Depending on the actual definition of what a
“brain” is (for example see Netsky, 1986) it is generally believed
that planarians represent the first type of organism possessing
an actual brain (Agata et al., 1998; Cebrià, 2007; Pagán, 2014;
Sarnat and Netsky, 1985, 2002; Okamoto et al., 2005; Umesono
et al., 2011). In addition to the general features of the planarian
nervous system that are similar to the nervous systems of more
“advanced” organisms, planarian neurons display closer similarities

to vertebrate neurons than to invertebrate neurons like insects, for
example, in terms of cell morphology and physiology (Sarnat and
Netsky, 1985, 2002). Structurally, the planarian central nervous
system consists of an anterior brain (sometimes referred to as
cephalic ganglia) and two longitudinal nerve cords, connected to
each other with nerve fibers arranged in a ladder-like structure
(Cebrià, 2007; Lentz, 1968; Okamoto et al., 2005; Fig. 4). Interestingly, most major neurotransmitter systems found in vertebrates are
also found in the planarian nervous system, which further argues
in favor of using this animal model in neurobiological investigations
(Buttarelli et al., 2008; Carolei et al., 1975; Ribeiro et al., 2005).
Additionally, planarians display a surprising variety of behavioral
responses induced by a wide range of compounds (for descriptions
of some of such behaviors please see Akiyama et al., 2015; Inoue
et al., 2015; Cochet-Escartin et al., 2015; Paskin et al., 2014; Raffa
et al., 2001; Raffa and Desai, 2005; Rawls et al., 2011; Talbot and
Schötz, 2011; Tallarida et al., 2014). These characteristics makes
planarians exceptional animal models in neurobiology, but their
usefulness does not stop there. Their varied and relatively complex
behavioral responses and the parallels between the anatomy and
physiology of the vertebrate and the planarian nervous systems
resulted in the development of planarians as a popular animal
model in pharmacology and its sister science, toxicology (Alonso
and Camargo, 2015; Best and Morita 1991; Li, 2016; Pagán et
al., 2009; Schaeffer, 1993; Stevens et al., 2015). In this review,
I emphasize the usefulness of planarians in pharmacological
studies, particularly in terms of neurobiology & behavior. For two
excellent reviews on planarian toxicology please see Hagstrom
et al.,2015, 2016).

The beginnings of systematic planarian pharmacology
research
When considering the fact that planarians share many biological features with “higher” organisms, together with their interesting
drug-induced behaviors, as well as their ease of use, it is no surprise
that planarians found their way into systematic pharmacological
research. In retrospect, it is rather surprising that it took so long.
It is important to point out that most of the pre-1970 planarian
research was not conducted with the explicit purpose of studying pharmacology, even though many compounds were tested in
this invertebrate. Rather, the main objective was
to use particular compounds in order to exploit
their specific pharmacological properties, by
slowing down or even paralyzing the worms to
facilitate the study of their anatomical or physiological characteristics. In fact, up to the 1970s,
there were quite a few publications describing
the effects of a variety of compounds and drugs
on planarians. More recently, the main emphasis
on the use of planarians in the pharmacological
sciences are the specific fields of behavioral- and
neuro-pharmacology (Buttarelli et al., 2008; Raffa
and Rawls, 2008). In the late 1960s-early 1970s
scientists began to realize that planarians showed
relatively complex behaviors when exposed to
Fig. 4. A general representation of the planarian
nervous system. Courtesy of Mr. Alexis G. Pagán.
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substances that induced psychoactive effects in “higher” organisms,
including vertebrates. Most interestingly, these worms displayed
various types of behavioral responses when exposed to drugs like
nicotine and cocaine. These planarian behaviors were evocative of
behaviors displayed by humans upon abused drug use, particularly
withdrawal-like behaviors related to physical dependence. These
facts caught the attention of clinical scientists, who reasoned that
planarians could be useful as models for the pharmacology of drug
abuse and other neurological diseases. In this light, the very first
report on the effects of a drug of abuse in planarians (morphine;
Needleman, 1967), was reported by a physician, Dr. Herbert
Needleman of Temple University, the pediatrician/psychiatrist who
is best known for his groundbreaking work on the neurotoxicity of
lead exposure and its effects on public health.
An ocean away in Rome, Italy, Drs. Antonio Carolei, Vito Margotta,
and Guido Palladini, neurologists at the University La Sapienza,
Rome, pioneered the systematic use of planarians in pharmacology
with the publication of their 1975 paper: “Proposal of a New Model
with Dopaminergic-Cholinergic Interactions for Neuropharmacological Investigations” (Carolei et al., 1975), coincidentally, the
same year when Krogh’s Principle was formalized (Krebs, 1975).
Once again, the remarkable regenerative properties of planarians were behind the interest of biomedical scientists, leading to
the use of these organisms as animal models. According to Dr.
Carolei (personal communication), in the 1970s he had a scientific
conversation with Dr. Palladini, that touched upon the topic of
immortality. Dr. Palladini observed that planarians were part of a
select group of animals that showed the potential for immortality due
to their unusual regeneration capabilities. This comment sparked
Dr. Carolei’s interest in planarian biology. Their formal scientific
rationale to study planarians was the analogous neural networks of
the motor system of planarians with the extrapyramidal system of
vertebrates, particularly their cholinergic/dopaminergic interactions.
The extrapyramidal system is a series of neuronal structures that
control multiple aspects of motor responses in vertebrates. The
dysfunction of this system leads to a variety of movement disorders
in humans, with Parkinson’s Disease as probably the best-know
example (reviewed in Dorman, 2015). In a short time, Drs. Carolei, Margotta, and Palladini, along with several other colleagues,
began to explore planarians as animal models for neurological
diseases with a neuropharmacological emphasis, and published
close to forty papers or book chapters between 1975 and 2008
on the pharmacology and neurobiology of the planarian Dugesia
gonocephala, also known as Dugesia japonica (reviewed in Buttarelli et al., 2008 and in Carolei et al., 2008a,b). Their planarianrelated publications dealt with a variety of pharmacological topics,
including the role of various neurotransmitter systems as well as
the effects of abused drugs like opiates, cannabinoids, and cocaine
(reviewed in Buttarelli et al., 2008 and in Carolei et al., 2008a,b). In
fact, they published the very first two papers that explicitly explored
the effect of cocaine in this experimental organism (Palladini et al.,
1996; Margotta et al., 1997). Planarians seemed to have a special
affinity for experimental neurologists; Drs. Harvey B. Sarnat and
Martin G. Netsky, then at UCLA, argued for the use of planarians
in the neurosciences (Sarnat and Netsky, 1985, 2002).
Thanks to the works of these clinical scientists, planarians caught
the attention of a group at Temple University, led by Dr. Robert
Raffa. Although a “traditional” pharmacologist, in his undergraduate university years he read about planarians in the context of

James McConnell’s memory retention work. Later on, Dr. Raffa
began his research projects on planarians at the suggestion of a
former colleague, and eventually joined efforts with another Temple
University pharmacologist, Dr. Scott Rawls. In 2000, the Temple
group published their first planarian pharmacology paper, which
was on the antipsychotic sulpiride and its antagonistic properties
against the neurotransmitter dopamine. As Drs. Carolei and Palladini before them, Raffa’s research was inspired on the similarities
between the planarian and mammalian dopaminergic systems
(Raffa et al., 2000). In 2001, the Raffa group published their first
cocaine/planaria paper (Raffa and Valdez, 2001), which was about
a series of behaviors reminiscent of “withdrawal symptoms” upon
exposure to cocaine to planarians. Just as the Rome team did, the
Temple University team began to explore (and continue exploring
at the time of this writing) the pharmacology of planarians. The
planarian pharmacology emphasis of the Temple team was (and
still is) abused drugs and their generation of specific planarian
behaviors that are similar to drug-related addiction behaviors in
vertebrates. Their chosen planarian species is Girardia dorotocephala. From the year 2000 to date, this group has published
close to 50 peer-reviewed papers or book chapters on planarian
behavioral pharmacology. Some of the specific drug-related topics that the Temple group study in their planaria-related research
include cross-sensitization (Rawls et al., 2010), anxiogenic-like
responses (Nayak et al., 2016), dose-related physical dependence
(Raffa et al., 2007), the dependence of drug exposure duration
related to the withdrawal response (Sacavage et al., 2008), and
abstinence-induced withdrawal among other related effects (Raffa
et al., 2008). Some drugs of abuse that were tested in their work
included cocaine, nicotine, amphetamines, opioids, cannabinoids,
and cathinones among others. Their work has been partially reviewed in Raffa and Rawls (2008).
Again, just like the Rome group did, the Temple group gathered
significant evidence indicating that planarians represents an interesting animal model, but more importantly, they further established
planarians as a model that displays close parallels with vertebrate
pharmacology. Both groups undoubtedly validated the usefulness
of these invertebrates in pharmacological research in general and
on the pharmacology of abused drugs in particular.

Planarians and the search for cocaine antagonists
One of the immediate research directions related to the pharmacology of drug abuse is the identification of compounds capable
of alleviating the behavioral or toxic properties of drugs. A premier
example of this approach was the development of naloxone as an
antidote against opioid overdose (Strang et al., 2016). An abused
drug that has resisted this approach is cocaine, which is an excellent
local anesthetic that is nonetheless a highly addictive substance
that has proved to be the direct cause of many overdose-related
fatalities (Loper, 1989; for a brief overview of the history and pharmacology of cocaine please see Pagán, 2014, chapter 5). So far,
the identification of a substance useful to clinically treat cocaine
intoxication has proven elusive (reviewed in Connors and Hoffman,
2013). There are several interesting links between planarians and
cocaine. Based on the most current available information online,
the two earliest publications describing planarian-like organisms
exposed to cocaine were an anonymous note in the journal The
American Naturalist (1891) and the second one was a report by
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Dr. Harold Heath, on the identification of a planarian species from
Hawaii, published in the Proceedings of the Academy of Natural
Sciences of Philadelphia (Heath, 1907). In both these works, the
main objective of using cocaine was to narcotize the worms so
they could be better examined.
It is important to point out that in the 1891 paper, the observed
organism, although called a planarian, was actually another type
of flatworm, an acoel, which is no longer recognized as a planarian
in phylogenetic terms (Ruiz-Trillo et al., 1999). Also, Dr. Heath’s
paper dealt with a marine flatworm, albeit a polyclad, which differs
from the “traditional” triclad planarians that we are discussing here
(Alvarez-Presas et al., 2008). Therefore, in strict terms, to the best
of my knowledge, the very first publications on planarians and
cocaine came from the Rome group, as discussed in the previous
section (Palladini et al., 1996; Margotta et al., 1997), followed by
the aforementioned publications of the Temple group. This means
that in strict terms, planarian/cocaine research is a mere 20 years
old at the time of this writing. I am honored by the fact that my own
laboratory has also provided information on the cocaine/planarian connection. I feel fortunate of having had the opportunity to
contribute to this scientific story and to continue doing so. What
follows is a brief account of the efforts of my research group at
West Chester University on the identification of behavioral cocaine
antagonists using the planarian model.
Parthenolide (Fig. 5) and related molecules are naturallyoccurring chemicals belonging to a class of compounds called
sesquiterpene lactones, which display a wide range of biological
effects; these compounds are commonly found in several species
of plants of the Asteracea family, parthenolide in particular is mainly
isolated from the feverfew plant (reviewed in Ivanescu et al., 2015
and in Pagán, 2005, chapter 5).
Preliminary data from my PhD dissertation (Pagán, 2005,
chapter 5) indicated that parthenolide showed antagonistic activity
against cocaine on both the nicotinic acetylcholine receptor and
the dopamine transporter using cell-based assays (reviewed in
Pagán, 2014, chapter 10). Based on these data, once I became
an independent investigator, I decided to study whether parthenolide or related compounds display anti-cocaine activity in vivo, as
opposed to the ex vivo (cell-based assays) approach previously
mentioned. Due to the multiple advantages that the planarian
model offers, and inspired by planarians papers dealing with their
neurobiology and pharmacology (Raffa and Valdez, 2001; Raffa
and Desai, 2005; Sarnat and Netsky, 1985, 2002), I chose these
worms as my experimental organism.
Our research demonstrated that parthenolide and related compounds indeed act as cocaine behavioral antagonists on the planar-

Fig. 5. The chemical structure of
Parthenolide.

ian model. Parthenolide antagonizes cocaine under conditions of
both acute administration (Pagán et al., 2008) as well as chronic
administration, effectively preventing the expression of withdrawallike behaviors (Rowlands and Pagán, 2008). We also explored the
structural features of parthenolide-like molecules that endowed them
with the ability to act as cocaine antagonists in planarians (Baker
et al., 2011), and provided evidence indicating that parthenolide
is a specific cocaine antagonist in this model (Pagán et al., 2012).
Also, using behavioral techniques developed in our laboratory, we
obtained information about the relative localization of the putative
binding sites of cocaine and nicotine in the planarian nervous
system (Pagán et al., 2013). Moreover, our collaborators at the
University of Puerto Rico, led by Dr. Carlos Jiménez-Rivera, found
that parthenolide blocks the effect of cocaine on the spontaneous
firing activity of dopaminergic nerve cells in the ventral tegmental
area of rats (Schwartz et al., 2010), therefore validating the Rome
group’s original insight; planarian pharmacology does indeed
seem to translate to vertebrate pharmacology, particularly that of
mammals (Buttarelli et al., 2008). To the best of my knowledge,
there are no other research groups using planarians to search for
antagonists of drugs of abuse, and much more work needs to be
done in this exciting area of research. This story is far from over.
In the next section, we’ll explore some trends about the scientific
publications on planarians and the pharmacological sciences.

A survey of published papers dealing with planarians
and pharmacology: 1900-2016
I began this review with the Krogh’s Principle as applied to model
organisms. Interestingly, the very same paper where he published
his insights on animal models (Krogh, 1929), included a thorough
analysis of the published papers on experimental physiology over
time, an approach similar to the one that I applied in this section,
with one major difference: Krogh did not have the advantage of
electronic databases to help him. I simply need to express my
admiration for his hard labor. On this note, for this section I used
the NIH’s PubMed database (http://www.ncbi.nlm.nih.gov/pubmed).
The searches included up to December 2016. Obviously, the results
reported here will be slightly different than the searches performed
at the time of publication of this review, as more papers are being
added to the PubMed database. However, this data will give us
a good idea on the publication trends related to planarians and
pharmacology. Also, please note that by necessity I chose the
search keywords arbitrarily. For example, to search articles about
planarians, I used the following array:
SEARCH 1 = (girardia OR dugesia OR schmidtea OR polycelis
OR phagocata OR planaria OR planarian OR planarians)
Which represent the five planarian genera that are most commonly used as research subjects as well as the variations on the
“planarian” term. I did not include terms like “flatworm” in these
search keywords because the results would then have included
papers about non-planarian organisms, like parasitic worms and
acoels, for example, which although quite interesting in their own
right, are beyond the scope of this review.
To search for the papers about pharmacology and planarians
I used the following array:
SEARCH 2 = (girardia OR dugesia OR schmidtea OR polycelis
OR planaria OR phagocata OR planarian OR planarians) AND
(pharmacology OR drug OR drugs OR pharmacological)
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The overall results for both SEARCH 1 and SEARCH 2 are
shown in Fig. 6. The data shows that of the planarian-related
papers published between 1900 and 2016, approximately 24 %
were of a pharmacological nature.
Next, I refined the results by using the PubMed feature that allows
for the custom selection of publication dates, as shown in Fig. 7.
The data in Fig. 7 indicates that there is a clear trend showing an increase on the number of planarian papers per year. The
same applies to planarian pharmacology papers, albeit to a lesser
extent, as expected due to the search constraints. Interestingly,
the data show a decrease on the number of planarian papers per
year between 1971 and 1990, which roughly correlates with the
decrease in popularity of the planarian model as a consequence
of the aforementioned controversial research of James McConnell.
Curiously, when the data are plotted as the fraction of planarian
papers dealing with pharmacology (Fig. 7, inset), it shows that about
40 % of the planarian papers published between 1971 and 1990
were related to pharmacology. It seems that even though planarians lost some popularity among the general scientific population,
it gained a relatively higher interest from pharmacologically-minded
scientists, arguably inspired by Dr. Carolei’s 1975 paper (Carolei et
al., 1975). For the last 25 five years or so, the percent of planarian
papers related to pharmacology has stabilized to about 24 % of the
total planarian-related papers (Fig. 7, inset), in close agreement
with the data shown in Fig. 6.
Please note that this database strategy used in this work is
limited by the fact that by necessity one needs to work with the
keywords explicitly stated anywhere within the text. This means
that there will be papers that albeit of a pharmacological nature,
may escape this search strategy because pharmacology-related
terms may not be explicitly stated in the text. Case in point: the
two earliest papers that came up in the planarian search (Moore,
1918; Stringer, 1917) dealt with the behavioral effects of strychnine
on planarians and starfish, and the effect of lithium chloride and
magnesium chloride on planarian locomotion respectively. Both
papers are undoubtedly pharmacological in nature, yet they were not
“caught” by the search. The main implication of this limitation is that
we are seeing an underestimation of the pharmacological-themed
planarian papers. To minimize this limitation, when searching for

Fig. 6. Published papers on planarians (SEARCH 1, see text), and on
planarians and pharmacology (SEARCH 2, see text). The numbers on
top of the bars represent the number of papers.

Fig. 7. Planarian (SEARCH 1) and planarian/pharmacology papers
(SEARCH 2) 1900-2016. Inset: Fraction of planarian papers that dealt with
pharmacological aspects (see text).

planarian papers on drugs of abuse, I used SEARCH 1 combined
with the appropriate keywords (i.e., cocaine, cannabinoid, etc.)
as shown in Fig. 8.
Fig. 8 shows an increasing trend in the publication of planarianrelated papers with a pharmacological theme, specifically about
drugs of abuse. The inset shows the number of planarian papers
that include keywords related to specific abused drugs 1900-2016,
as indicated. It is fully expected that this trend will continue.

The future: developmental and regeneration
pharmacology: Planarians lead the way.
Regular readers of this journal are quite familiar with the formal
distinctions between the processes of development and regeneration. Therefore, I will not revisit their respective definitions here
except to say that these are two closely related areas, with important
similarities and differences in terms of their specific mechanisms
and physiological aspects. Nonetheless, in many instances they
are treated as one and the same phenomenon, even in scientific
publications, which oftentimes leads to controversy, a controversy
that is beyond the scope of our discussion. For a review of the
similarities and differences between the phenomena of development and regeneration please refer to Vervoort (2011).
Efforts regarding the advance of developmental pharmacology
are mainly focused on the neonatal and pediatrics application of
such principles (Kearns et al., 2003; Samardzic et al., 2015). The
overwhelming majority of the literature in this area deals primarily
with aspects of dosage, as well as the ADME pharmacological
principle (Administration, Distribution, Metabolism, and Elimination)
and their effect on the normal development of young patients. These
young patients were widely referred to as “therapeutic orphans”
because of the relative lack of data regarding the effects of age
on pharmacological treatments (Berde and Cairns, 2000). I was
unable to obtain any publications on the correction of fully understood developmental defects through pharmacological approaches.
Probably the only example of this practice in preventive medicine
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Fig. 8. Planarian (SEARCH 1) combined with various search terms
associated with drugs of abuse as indicated in the inset. (SEARCH
2) 1900-2016. Inset: The same data separated into the individual drugs of
abuse, as indicated.

is the supplementation of folic acid to pregnant women, shown to
decrease the risk of neural tube defects, a congenital defect that
prevents the proper closure of the neural tube. However, even in
this case, the genetic and biochemical mechanisms of such protective effect are largely unknown (Imbard et al., 2013).
As in the case of developmental pharmacology, most of the
scientific literature on regeneration pharmacology is oriented
towards applications to the clinical sciences, specifically with the
repair of various organ systems. In fact, a formal definition of the
field of regenerative medicine in general is the “… repair and/or
replacement of damaged cells, tissues, and organs for functional
restoration” (Christ et al., 2013). Regeneration pharmacology aims
to the integration of several “traditional” aspects of regenerative
medicine, namely molecular biology, biomaterials and tissue engineering, nanotechnology, and physiology among others, with a
pharmacological approach (Andersson and Christ, 2007; Christ
et al., 2013).
In this final section of this review, I argue in favor of planaria as
the proverbial “flagship” animal model in developmental pharmacology and regeneration pharmacology. This class of organisms
possesses a unique set of characteristics that makes it particularly
endowed to serve as a link to connect the research efforts of scientists of different disciplines.
Planarians have long been proposed as useful animal models
for regenerative medicine (Gentile et al., 2011; Karami et al., 2015;
Matthews and Levin, 2016; Umesono et al., 2011). Also, traditionally,
planarian worms have been used as an animal model in developmental biology, mainly because many planarian species possess
the extraordinary ability of completely regenerating lost body parts
(Reddien and Sánchez Alvarado, 2004; Sánchez Alvarado, 2006;
Newmark et al., 2003; Sánchez Alvarado, 2004a,b). In strict terms,
most organisms are capable of some degree of regeneration, and
in general, the closer they are to the vertebrate line, the lesser the
regenerative abilities they may display. There are other organisms
which are as remarkable, if not more, as planarians are in terms

of regenerative properties. Well-known examples are certain
sponge species and the small freshwater cnidarian hydra. These
two types of organisms tolerate complete cell dissociation and in
the absence of any chemical insults, are able of reforming their
entire body structure (Alexander et al., 2015; Holstein et al., 2003).
This is an extreme capability not shared by planarians. It is without
dispute that sponges and cnidarians are invaluable regeneration
models. What sets planarians apart in terms of regeneration and
development is that they are relatively complex organisms in terms
of organ structure (Roberts-Galbraith et al., 2015). Moreover,
the regenerative prowess of some planarian species include the
complete regeneration of the brain and nervous system (Agata
and Umesono, 2008; Cebrià, 2007; Cebrià and Newmark, 2002;
Cebrià et al., 2002; Fraguas et al., 2012; Umesono and Agata,
2009; Umesono et al., 2011). These facts, alongside the aforementioned relatively complex behaviors that these organisms express
naturally and in response to exposure of a variety of drugs, make
planarians unique organisms to integrate the fields of regeneration,
developmental biology, and pharmacology.
Another advantage of the use of the planarian model in this context is that they are very well characterized in genomic terms. Since
2007, the Schmidtea mediterranea Genome Database (SmedDB;
http://smedgd.stowers.org), now in its second generation (Robb et
al., 2015) has provided a much needed resource where genomic
and transcriptomic studies from this organism are compiled (For
examples please see Abril et al., 2010, Nishimura et al., 2012,
and Resch et al., 2012). Transcriptomic analyses have also been
performed in Dugesia japonica (Chan et al., 2016; Nishimura et
al., 2012, 2015; Pang et al., 2016; Qin et al., 2016).
As useful as molecular approaches are, allow me to offer a
note of caution on the use of inbred and clonal strains from a
pharmacological perspective. Natural populations of any organism will generally display some degree of genetic variability. This
is an integral aspect of the evolutionary process. This means
that in such natural populations we would expect to see a correspondent degree of variability in the pharmacological responses
induced by any tested drug or toxin. The human pharmacogenetic
variability observed by the expression of multiple phenotypes in
response to a single drug also applies to our fellow organisms on
this planet. The study of the pharmacologically diverse effects on
non-homogeneous populations will paint a more realistic picture
of the incidence of any pharmacologically-related phenotypes than
studies on clonal lines. Natural populations are exposed to various
types of environmental stimuli that contribute to selective pressure,
an established occurrence that is widely considered a driving force
on evolution, whether it comes from biotic or abiotic factors. One
of the consequences of such pressure is genetic heterogeneity
in a population. In these lines, the planarians currently used to
model the genetic data (S. mediterranea and Dugesia japonica)
are usually more genetically uniform than natural populations. It is
important to reiterate that there is no doubt that studies on clonal
lines provide essential information about fundamental biological
processes. Nonetheless, I submit that any pharmacological conclusion based exclusively on such planarian clonal lines must be
examined in light of data obtained from more natural populations
in order to refine and complement the information obtained through
populations of genetically similar organisms. Several species of
planarians of the Girardia, Dugesia, and Phagocata genera are
currently commercially available through several suppliers and are
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therefore available for such pharmacological studies.
Another important bioinformatics approach designed to store and
disseminate planarian regeneration-related research is the development of the Planform database (PlanformDB; http://lobolab.umbc.
edu/planform/; Lobo et al., 2013). This database collects more than
a thousand separate published experiments and just as SmedGD,
PlanformDB is under constant expansion. In contrast to SmedGD,
PlanformDB includes information from a wider range of planarian species. There is little doubt that SmedGD and PlanformDB
complement each other and their interaction will surely facilitate the
exchange of information between scientists across different disciplines, significantly advancing the progress of planarian research.
A recent series of quite interesting experiments perfectly showcase the integration of the disciplines of development, regeneration,
and pharmacology. The research that I will briefly describe comes
from the laboratory of Dr. Michael Levin of Tufts University. The basis
of their work is the recognition that bioelectrical properties play a
central role in regeneration phenomena (Durant et al., 2016; Levin
2012, 2014). Specifically, they have explored the pharmacological
manipulation of gap junctions, which are channels between cells
formed by specific proteins (connexins) that modulate the connections between cells. Connexins selectively allow the exchange
of their internal components, which frequently include ions. Thus,
these proteins modulate the bioelectrical properties between cells.
These proteins are being recognized as modulators of the planarian
stem cell response as related to tissue maintenance, repair, and
remodeling (Peiris and Oviedo, 2013).
By pharmacologically treating planarians with n-octanol, a
connexin blocker, they were able to modulate the physiology of
planarian stem cells from Dugesia japonica to induce the formation
of multiple heads and their associated neural structures (Oviedo
et al., 2010). In a related note, ectopic brain tissue formation in
planarians was also observed a few years ago by modulating the
function of fibroblast growth factor receptors (Cebrià et al., 2002).
The recent work by the Levin laboratory describes a series of experiments (Emmons-Bell et al., 2015) in which they treated decapitated
planarians of a commercially available planarian species (Girardia
dorotocephala) with 123 mM n-octanol for three days. After this period, the n-octanol was washed away and the worms were allowed
to regenerate for seven additional days. Many worms regenerated
normally (about 35 % of the total), but a significant fraction of them
differed drastically on their head morphology; these worms’ head
shapes were closely similar to the head shapes of different planarian species, which they referred to as “pseudo-X”, X being Girardia
dorotocephala, Dugesia japonica, Polycelis felina, and Schimidtea
mediterranea (Fig. 9). In addition to the appearance of various head
shapes in the regenerating planarians, three additional aspects of
this series of experiments are quite significant: (1) The proportion
of the head shapes developed of the total planarians tested (i.e.,
the relative percentages of pseudo-Girardia, pseudo-Dugesia,
pseudo-Polycelis, and pseudo-Schmidtea), (2) Their associated
brain structures and distribution of neoblasts (planarian stem cells),
and (3) The eventual return to the original Girardia-like head shape,
as if the original genome of the planarian was “reasserting” itself. In
brief, the number of planarians regenerating specific head shapes
roughly correlated with the phylogenetic distance from the parent
species (G. dorotocephala). Most of the worms regenerated the
parent form (~35 %), followed by pseudo-D. japonica (~30 %),
pseudo-S. mediterranea (~15 %), and pseudo-P. felina (~5 %; Fig.

Fig. 9. Excerpt of the main results of Emmons-Bell et al., (2015) on
the transient pharmacological modification of the apparent phenotype of
regenerating Girardia dorotocephala (see text). Illustration courtesy of Mr.
Alexis G. Pagán.

9). Fifteen percent of the worms failed to regenerate. Interestingly,
the morphological differences were not limited to their head shape;
their brain connectivity and overall morphology were changed as
well, resembling that of the “pseudo” species. Finally, the change in
head morphology was transient. When the worms were allowed to
regenerate beyond day 10, they reverted to a shape similar to the
parental form, again, roughly in phylogenetic distance order, as if
their “native” genome was reactivated. This differed from previous
experiments where the formation of additional heads in D. japonica
was a permanent phenomenon (Oviedo et al., 2010). The Levin
group further proposed the beginnings of a model that describes
how bioelectrical properties can be manipulated to generate distinct
morphologies.
From the perspective of the main topic of this review, the results
described in Emmons-Bell et al.,2015) seems to represent the first
demonstration where pharmacology, regeneration, and development
were explicitly related in an experimental framework. In essence,
the pharmacological manipulation of connexins disrupted the normal
regeneration of G. dorotocephala to G. dorotocephala, inducing the
development of the pseudo-D. japonica, pseudo-S. mediterranea,
and pseudo-P. felina heads as well as their corresponding brain
morphologies, which subsequently “re-developed” into their original
phenotype. If and when developmental biology, regeneration biology,
and pharmacology become truly integrated into a bona fide area
of research, Emmons-Bell et al.,2015) should be recognized as a
landmark study of this emerging interdisciplinary field.

Conclusions and Perspectives
The fields of planarian pharmacology and neuroscience are
undergoing an interesting period of expansion. This includes the
exciting interdisciplinary areas of developmental and regeneration
pharmacology. I strongly believe that the interdisciplinary nature of
this novel approach using planarians must begin with a perspective shift on behalf of the relevant scientists. In other words, a
pharmacologist should be as conversant and comfortable talking
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about imaginal discs and stem cells as when talking about receptor theory. The same reasoning applies to the developmental and
regeneration biologist. I speak from experience. When I submitted
our group’s first paper linking regeneration and pharmacology
(Pagán et al., 2013), the specific areas of expertise of the paper’s
reviewers (i.e., pharmacology vs. developmental biology) were immediately apparent. In a way, when responding to the reviewers I
felt like a diplomat coordinating a summit between two superpowers
that spoke different native languages. To have a first row seat while
to scientific disciplines begin to formally collaborate is a singular
honor for a scientist. Some of the immediately apparent benefits
from the synergy of regeneration, development, and pharmacology research will surely include the clarification of the fundamental
processes that control how an organism develops and regenerates.
Moreover, this research could point the way to the discovery of
small molecules that affect these processes, potentially allowing
their pharmacological manipulation with obvious implications for
the medical sciences. Conversely, a more complete understanding
of regeneration and development could shed light important pharmacological mechanisms, as it is a well-established fact that the
specific effect of many drugs is dependent on the developmental
stage of the subject. I believe that this is just the beginning of a
significant wave of advances in the biomedical sciences. Planarians are exceptionally positioned to help us achieve this goal, and
therefore they should lead the way.
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